Author: United States. Congress. Senate. Committee on Human Resources. Subcommittee on Health and Scientific Research
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 252
Book Description
Preclinical and Clinical Testing by the Pharmaceutical Industry, 1977
Preclinical and Clinical Testing by the Pharmaceutical Industry, 1979
Author: United States. Congress. Senate. Committee on Labor and Human Resources. Subcommittee on Health and Scientific Research
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 108
Book Description
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 108
Book Description
Preclinical and Clinical Testing by the Pharmaceutical Industry, 1976
Author: United States. Congress. Senate. Committee on Labor and Public Welfare. Subcommittee on Health
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 1340
Book Description
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 1340
Book Description
Preclinical and Clinical Testing by the Pharmaceutical Industry, 1975[-1976]
Author: United States. Congress. Senate. Committee on Labor and Public Welfare. Subcommittee on Health
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 490
Book Description
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 490
Book Description
Preclinical and Clinical Testing by the Pharmaceutical Industry, 1979
Author: United States. Congress. Senate. Committee on Labor and Human Resources. Subcommittee on Health and Scientific Research
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 84
Book Description
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 84
Book Description
Preclinical and clinical testing by the pharmaceutical industry, 1977
Author: United States. Congress. Senate. Committee on Human Resources. Subcommittee on Health and Scientific Research
Publisher:
ISBN:
Category :
Languages : en
Pages : 340
Book Description
Publisher:
ISBN:
Category :
Languages : en
Pages : 340
Book Description
Preclinical and Clinical Testing by the Pharmaceutical Industry, 1975
Author: United States. Congress. Senate. Committee on Labor and Public Welfare. Subcommittee on Health
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 264
Book Description
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 264
Book Description
Preclinical and Clinical Testing by the Pharmaceutical Industry, 1975
Author: United States. Congress. Senate. Committee on Labor and Public Welfare. Subcommittee on Health
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 1622
Book Description
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 1622
Book Description
Preclinical and Clinical Testing by the Pharmaceutical Industry, 1975-
Author: United States. Congress. Senate. Committee on Labor and Public Welfare
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 344
Book Description
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 344
Book Description
Improving and Accelerating Therapeutic Development for Nervous System Disorders
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309292492
Category : Medical
Languages : en
Pages : 107
Book Description
Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.
Publisher: National Academies Press
ISBN: 0309292492
Category : Medical
Languages : en
Pages : 107
Book Description
Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.